Drug Trial Radar · NCT07597902
SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction
Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Oct 20, 2026
Primary completion
Jun 30, 2028
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- Icahn School of Medicine at Mount SinaiAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- PridCor Therapeutics
- First posted
- May 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this research study is to test if the combination of three drugs, valacyclovir, celecoxib, and Paxlovid will decrease the symptoms of Long COVID in adults compared to a placebo (this does not contain the medications).
Conditions
- Post-acute Sequelae of COVID-19
- Long COVID
Interventions
ValacyclovirDrug
one to two 750mg capsules taken orally in the morning and evening
CelecoxibDrug
200mg capsules taken orally in the morning and evening
PaxlovidDrug
one (100mg ritonavir tablet and two 150mg nirmatrelvir tablets) taken orally in the morning and evening
PlaceboDrug
matching placebo capsules and tablets taken orally in the morning and evening
Primary outcomes
What the sponsor says the trial is designed to measure.
- EQ-5D-5L Visual Analogue Scale (VAS)Time frame: Baseline (Week 1), Week 4, Week 8, Week 12, Week 16, Week 20
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Cohen Center for Recovery from Complex Chronic Illnesses (CoRE)
New York, New York · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.